Lipman: Synbio startups should prioritize niche, high-value markets
Ari Lipman · Microbes, meat and materials: biotech meets climatetech · Jan 18, 2022 · at 30:24
Ari Lipman discusses synthetic biology go-to-market strategies with Shayle Kann on Catalyst.
0:00 / 0:19exact quote · 19.4s
720p mp4 · rendered on demand · StarZero watermark
“You know, you always want to try to own a larger portion of a small market than try to own a small portion of a large market, at least at the outset. So I think, and that has been the tradition across the biotech industry and across synthetic biology is go for the highest value products possible first, or maybe some of the smaller, more niche markets where your go to market strategy is a little bit easier.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Ari Lipman
Lipman: Synbio cell engineering as software is mostly marketing
“Many of the sort of publics in bio companies or the leadings in bio companies will talk about their, you know, cell engineering platform as if it's a software platform. We're really not there yet. It's more marketing than anything else in my opinion at the mom…”
Lipman: Most lab-grown meat startups will fail to reach commercial scale
“I'm anticipating that the vast majority will not be able to reach commercial scale and not be able to reach the market, so we'll either see a bunch of consolidation or a bunch of dead companies in the wake of whatever reckoning may be coming.”
Lipman: Carbon-neutral products no longer strictly require price parity
“No, I think that's something that's changed in the environment is that
you don't necessarily have to be at price parity. It seems like in some of these industries or some of these products to be successful. So
It seems like consumers and, you know, certain …”
Lipman: Downstream processing accounts for most industrial biomanufacturing costs
“Most of the cost actually comes in the downstream processing. So after you grow up these cells in these big steel tanks the vast majority of costs come after that phase where you have to process this wet biomass and spin it down and treat it and purify it.”